International: Manufacturing Site Divestitures

In brief

Pharmaceutical companies are increasingly outsourcing complex manufacturing activities to contract development and manufacturing organizations (CDMOs). This enables pharmaceutical companies to streamline their operations and redeploy capital toward research and development activities. At the same time, the CDMO industry is booming, with many analysts predicting continued rapid growth. CDMOs need more capacity, and they need it quickly. As a result of these trends, many pharmaceutical companies are engaging in an increasing number of transactions in which they divest manufacturing sites to CDMOs.

Read the full version of International: Manufacturing site divestitures.